Tumour-associated Antigens and Gene Products in Diagnosis and Treatment

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to the identification and use of tumor-associated antigens (TAAs) and their gene products for the diagnosis and treatment of cancer. The patent covers pharmaceutical compositions containing agents (such as antibodies, antisense molecules, or small molecules) that specifically detect or inhibit the expression or activity of TAAs, which are proteins or nucleic acids found predominantly in tumor cells but not in normal tissues. These agents can be used to target, identify, or destroy tumor cells for more precise cancer diagnosis and therapy.

Use CasesContent extracted from patent full text and abstract with AI.

• Developing diagnostic tests (e.g., PCR, ELISA, imaging agents) to detect specific TAAs in cancer patients for early or differential cancer diagnosis.
• Designing targeted cancer therapies using monoclonal antibodies or antisense molecules that bind to or inhibit TAAs, leading to tumor cell death or reduced proliferation.
• Creating personalized immunotherapies or cancer vaccines based on the identified TAAs to stimulate the patient's immune system to recognize and attack cancer cells.
• Monitoring disease progression, treatment response, or cancer recurrence using TAA levels as biomarkers in blood or tissue samples.
• Combining TAA-targeting agents with conventional chemotherapeutics or radiologics for synergistic anti-cancer effects.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides higher specificity for cancer cells, reducing harm to normal tissue and minimizing side effects compared to conventional therapies.
• Enables earlier and more accurate cancer diagnosis through detection of tumor-associated biomarkers.
• Allows personalized treatment strategies tailored to the patient's tumor antigen profile, potentially improving outcomes.
• Makes possible targeted delivery of therapeutic agents (such as toxins, cytostatics, or nanoparticles) directly to cancer cells, increasing treatment efficacy.
• Supports better monitoring of treatment efficacy and disease progression through measurable molecular markers.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a pharmaceutical composition comprising an agent which detects or inhibits the expression or activity of a tumour-associated antigen, and to a method for the treatment and diagnosis of a tumour disease. These agents and methods make it possible to offer target structures for the diagnosis and treatment of diseases, in particular cancers.